OPTIMAL DURATION OF ADJUVANT TRASTUZUMAB THERAPY IN PATIENTS WITH HER2-POSSITIVE EARLY BREAST CANCER: WHETHER THE PROBLEM IS RESOLVED? ArticleZhukova L.G., Ganshina I.P., Khatkova E.I., Tikhomirova T.E., Kondratyeva O.E.Современная онкология. Vol. 20. 2018. P.. 24-28
